drugset / Trial / NCT06066216
Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer
Phase 2
Not yet recruiting
45 enrolled
Fujian Cancer Hospital
Fujian Provincial Hospital · collabThe First Affiliated Hospital of Bengbu Medical University · collabThe First Affiliated Hospital of Nanchang University · collabZhangzhou Affiliated Hospital of Fujian Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, multi-center Phase II study of cadonilimab (AK104) combined with chemotherapy in patients with recurrent or advanced endometrial cancer. The primary objective is to evaluate objective response rate of cadonilimab plus chemotherapy.
Timeline
- Start
- 2024-02-01
- Primary completion
- 2025-10-31
- Completion
- 2026-10-31
Publications
- Liu B, Chen J, Chen L, Chen X, Zhuo Y, Yang L, Li Y, Lin J, Guo X, Lin Y, Liu T, Zou J, Jiang Y, Sun Y. Efficacy and safety of cadonilimab combined with chemotherapy as first-line treatment for primary advanced or recurrent endometrial cancer: An interim analysis of a prospective, single-arm, open-label phase II trial. Gynecol Oncol. 2026 Apr;207S:14-22. doi: 10.1016/j.ygyno.2026.03.014.
- Lin J, Liu T, Chen J, Lin Y, Chen X, Zhuo Y, Li Y, Jiang Y, Yang L, Tu C, Liu B, Zou J, Chen L, Sun Y. Efficacy and safety of cadonilimab combined with chemotherapy as the first-line treatment for primary advanced or recurrent endometrial cancer: a prospective single-arm open-label phase II clinical trial. BMJ Open. 2025 May 19;15(5):e094649. doi: 10.1136/bmjopen-2024-094649.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Background | Carboplatin | Small molecule | — | — |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Background | Paclitaxel | Small molecule | 175 mg/m2 | — |